Objective(s): HIV-positive individuals have elevated rates of anal squamous cell carcinoma (SCC), and sexually transmitted infections with its causative agent, high-risk human papillomavirus, and other oncoviruses including hepatitis B virus (HBV). HBV infection can cause liver cancer, and has been associated with increased risk of some extra-hepatic cancers including biliary tract cancer, pancreatic cancer, and non-Hodgkin lymphoma. Whether HBV is associated with anal SCC risk is unknown.
Introduction
Hepatitis B virus (HBV) infection is a risk factor for hepatocellular carcinoma (HCC), and is also associated with elevated risk for some other types of cancer including pancreatic cancer [1] [2] [3] [4] [5] and non-Hodgkin lymphoma (NHL) [6] [7] [8] [9] . The mechanisms by which HBV infection increases risk of some extra-hepatic cancers are unclear. However, its protumorigenic effects raise the possibility it could be an oncogenic cofactor [10] [11] [12] [13] [14] [15] .
HBV infection rates are high among HIV-infected populations and MSM [16] [17] [18] [19] . HIV-infected populations have elevated risk for non-AIDS-defining malignancies (NADMs) linked to infections with oncoviruses such as HBV or hepatitis C (HCC) and high-risk human papilloma virus (hrHPV) (genital, anal, and oropharyngeal cancers) [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . Anal squamous cell carcinoma (SCC) is a NADM caused by hrHPV in more than 90% of cases [32] . Anal hrHPV infections are detected in 30-90% of HIV-positive individuals, with the highest rates among MSM [32] [33] [34] [35] [36] [37] . However, other factors are required for tumorigenesis [38] . Known risk for anal SCC factors include multiple sexual partners, immunodeficiencies, and smoking [39] [40] [41] [42] .
Synergistic syndemic interactions between hrHPV and HBV in promoting high-grade squamous intraepithelial lesions (HSIL) were suggested by a previous study [43] . Furthermore, anal hrHPV is more prevalent among individuals with prior HBV [44] or hepatitis [45] . Here, we evaluated the association between prior HBV infection and anal SCC risk in a prospective cohort of HIV-positive and HIV-negative MSM enrolled in the Multicenter AIDS Cohort Study (MACS).
Methods
Study cohort This is a nested prospective cohort study in the MACS, an ongoing study established in 1984 that has enrolled 7343 HIV-positive and HIV-negative MSM. Clinical and laboratory data were collected at semiannual visits as described [25, 39] . Eligible participants were 5298 MSM aged 30-70 years with at least 5 years of follow-up during 1984-2014 and one or more visits with HBV laboratory test data. Baseline was first visit after age 30 years. Institutional Review Boards at each study site approved the research and all participants provided written informed consent.
Data collection, risk factor classification, and cancer outcomes
The MACS public dataset release 25 was used for analyses. Past or current HBV infection was a time-invariant categorical variable defined by two or more positive lab tests for anti-HBV core antigen (ATHBC), HBV surface antigen (HBSAG), HBV e antigen (HBEAG), or HBV DNA (n ¼ 2001), or single positive result for HBSAG (n ¼ 29) or HBEAG (n ¼ 1) any time following enrollment to study endpoint. Incident cancers were classified as described [25] .
Statistical analysis
Participants were followed from baseline to first instance of incident cancer, last study visit, or age 70. Poisson regression models were restricted to HIV-positive participants. Factors associated with anal SCC in univariate analyses at P less than 0.2 were entered in the multivariate model, with stepwise backward selection used to retain significant features in the model (P < 0.05). Race and HAART use were retained in models as potential confounding factors. Models were sequentially adjusted for additional covariates having known associations with anal SCC risk and/or HBV. Statistical analysis was performed in R version 3.2.4 (R Project for Statistical Computing, Vienna, Austria).
Results

Demographic and behavioral characteristics by HIV and hepatitis B virus infection status
We identified 5298 MSM ages 30-70 enrolled in the MACS during 1984-2010 and contributing 79 334 person-years, with median follow-up of 12 years (Table  1) . Thirty-eight percent (n ¼ 2037) had past or current HBV infection at endpoint based on positive tests for ATHBC, HBSAG, HBEAG, and/or HBV DNA, of which 87.7% were positive at enrollment and 21% had one or more positive tests for HBSAG, HBEAG, and/or HBV DNA within follow-up. Age at endpoint, followup time, and frequencies of anal SCC and other NADMs were higher among participants with past or current HBV in comparison with HBV-negative participants. By contrast, frequencies of HIV-positive participants with ADMs or death were lower among participants with past or current HBV in comparison with HBV-negative participants. More HIV-negative participants with past or current HBV reported more than two sexual or anal receptive partners/6 months in comparison with HBVnegatives, whereas there was no difference by HBV status among only HIV-positive participants.
Immunological and virological characteristics by HIV and hepatitis B virus infection status
CD4 þ cell counts and CD4 þ : CD8 þ ratios were lower in HIV-positive compared with HIV-negative participants, whereas the relationship of these variables to HBV status varied by HIV status (Table 1 ). Among HIV-negative participants with past or current HBV, CD4 þ cell counts and CD4 þ nadirs were lower at 1 year prior to endpoint in comparison with HBV-negative . Among HIVpositive participants with past or current HBV, CD4 þ cell counts and CD4 þ : CD8 þ ratios were higher, fewer participants had CD4 þ cell counts less than 350 cells/ml at [30, 39] 35 [30, 41] 34 [30, 40] 36 [31, 42] 34 [30, 38] 34 [30, 40] Age at endpoint (median [IQR]) 45 [39, 53] 56 [47, 63] 48 [41, 56] 60 [52, 66] 43 [38, 50] 53 [45, 60] Cumulative person-years (median [IQR]) 11 [7, 13] 20 [12, 28] 11 [9, 17] 24 [12, 30] 9 [6, 12] 14 [11, 27] Race White 1 year prior to endpoint, and HAART or HBV-active medication use was more frequent in comparison with HBV-negative participants ( Table 1) . 
Hepatitis B virus and anal squamous cell carcinoma risk in HIV-positive subjects
In univariate models, past or current HBV was associated with increased risk of anal SCC in HIV-positive participants (IRR, 95% CI 4.92, 2.09-11.63), as was older age and CD4 þ cell counts less than 500 or CD4 þ : CD8 þ ratios less than 0.5 lagged 6 years prior to endpoint (Supplemental Digital Content 2, http:// links.lww.com/QAD/B386). The association remained significant in multivariate models adjusted for age, race, HAART use, and CD4 þ cell counts or CD4 þ : CD8 þ ratios (IRRs, 95% CIs 3.07-3.29, 1.24-7.64 to 1.32-8.23; Table 2 ). In subanalyses of either past or current HBV compared with HBV-negative participants, only past HBV had a significant association with anal SCC risk (IRRs, 95% CIs 3.39-3.71, 1.32-8.75 to 1.42-9.67; Table 2 ). Further adjustment for HCV infection, number of sexual partners, tobacco use, or poppers use did not attenuate this association (Table 2 ). CD4 þ cell counts less than 500 or CD4 þ : CD8 þ ratios less than 0.5 at 6 years prior to endpoint were associated with increased anal SCC risk in adjusted models ( Table 2 ). CD4 þ cell counts less than 500 or CD4 þ : CD8 þ ratios less than 0.5 at 1 year prior to endpoint were significant only in adjusted models, whereas nadir values were marginally significant (Supplemental Digital Contents 2 and 3, http:// links.lww.com/QAD/B386 and Table 2 ). A negative association between no HAART use at endpoint and anal SCC risk was significant in unadjusted, but not adjusted models. Older age had a strong association with increased anal SCC risk in adjusted models, tobacco use had a marginally significant association (IRRs 1.60-1.83; P ¼ 0.068-0.159) (Supplemental Digital Content 3, http://links.lww.com/QAD/B386), and race, number of sexual partners, HCV infection, or poppers use had no significant associations (Table 2) .
Demographic and clinical characteristics of groups by HIV status and anal squamous cell carcinoma diagnosis
We compared characteristics of the cohort stratified by HIV and anal SCC diagnosis (Supplemental Digital Content 4, http://links.lww.com/QAD/B386). Among HIV-positive participants, lab values indicating past HBV infection were more common among anal SCC cases compared with noncases. Similar trends were observed among HIV-negative participants. Anal SCC cases were older at endpoint, with longer follow-up and lower death rates in comparison with noncases among HIV-positive participants, anal SCC cases had lower CD4 þ cell counts and CD4 þ : CD8 þ ratios lagged 6 years prior to endpoint among HIV-positive participants and lower nadir CD4 þ cell counts and nadir CD4 þ : CD8 þ ratios compared with noncases in HIV-negative participants. HAART and HBV-active medication use were more common among anal SCC cases compared with noncases.
Discussion
In this prospective study of 5298 MSM enrolled in the MACS from 1984 to 2014, past or current HBV was associated with three-fold increased risk of anal SCC among HIV-positive participants, and remained an independent risk factor in models adjusted for age, HAART use, CD4 þ cell counts or CD4 þ : CD8 þ ratios, and other risk factors. We also confirmed previously reported associations between anal SCC risk and older age, decreased CD4 þ cell counts or CD4 þ : CD8 þ ratios, and smoking. Together with prior studies demonstrating increased HSIL among individuals coinfected with anal hrHPVand HBV [43] , our findings suggest that HBV may be an oncogenic cofactor for development of anal SCC.
The association between HBV infection and anal SCC occurred primarily in HIV-positive participants with resolved HBV [46] . In analyses limited to active or chronic HBV, the association between HBV and anal SCC was NS. Similarly, Hassan et al. [1] found the association between HBVand increased risk of pancreatic cancer was evident in ATHBC-positive, HBSAGnegative individuals. These findings raise the interesting question of how resolved HBV infections might impact cancer risk later in life.
HBV has been associated with elevated risk of several nonhepatic cancers and NHL [1] [2] [3] [4] [5] [6] [7] [8] [9] . HBV integrates into host DNA, causing insertional mutagenesis, and encodes the oncogenic hepatitis B X protein, which targets tumor suppressor and DNA damage repair pathways [10, 12, 13, 15] . With regard to indirect roles in promoting risk of anal SCC, HBV induces inflammation and T-cell exhaustion [11, 14] and cirrhosis can lead to immune dysregulation and CD4 þ lymphopenia [47] [48] [49] . However, immunological effects of resolved HBV infections are unknown. We found a significant association between low CD4 þ cell counts or CD4 þ : CD8 þ ratios at 6 years prior to endpoint and anal SCC risk, consistent with [50] . Further studies are warranted to determine if resolved HBV is associated with immunological effects that impact later risk of cancers.
Participants on HAART had greater risk of anal SCC in comparison with those not on HAART, consistent with [39, 50] . AIDS-related deaths are a competing risk and HAART prolongs life expectancy, allowing more time during which precursor lesions can progress to anal cancers [39, 40, [50] [51] [52] .
We acknowledge limitations of our study. Lack of data related to hrHPV infection precluded modeling its role in anal SCC carcinogenesis. Our study was limited to mostly white MSM in a cohort at high risk of acquiring HIV, HBV, and HPV, with high rates of smoking and substance use, limiting applicability of our findings to the general population. HIV-positive participants with past or current HBV were slightly older, with more HAART and HBVactive medication use, better immunological profiles, and lower death rates. However, a case-control analysis in which each anal SCC case was matched to 10 controls based on recruitment wave, age at enrollment, race, HIVinfection status, smoking, follow-up, and calendar year at endpoint supported all of our main conclusions (data not shown).
In conclusion, this study demonstrates a significant association between prior HBV infection and increased anal SCC risk independent of age, HAART use, and immunological parameters. These results have implications regarding potential benefits of anal SCC screening in HIV-negative and HIV-positive MSM with prior HBV, and suggest that HBV vaccination in at-risk populations has the potential to improve anal cancer prevention.
